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Abstract: Multiple myeloma (MM) is the second most common hematologic malignancy in the 
US. It is typically characterized by production of large amounts of defective immunoglobulin 
(Ig). Diagnosing MM and monitoring treatment response, including eventual relapse, are largely 
based on sequential measurements of Ig. However, a small subset of MM called non-secretory 
multiple myeloma (NSMM) produces no detectable Ig. This subset of true NSMM has become 
even smaller over time, as the advent of the serum free light chain assay has resulted in the 
majority of NSMM patients being recategorized as light-chain MM – that is, MM cells that 
produce only the light-chain component of Ig. True forms of NSMM, meaning MM that secretes 
no monoclonal proteins whatsoever, constitute a distinct entity that is reviewed; definition of 
NSMM using current detection methods, discuss the biology underpinning NSMM develop-
ment, and share recommendations for how NSMM should be managed clinically with respect 
to detection, treatment, and monitoring.
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Introduction
Multiple myeloma (MM) is the second most common hematologic neoplasm in the 
US, with ~30,000 new cases annually.1 It is a malignancy of terminally differentiated, 
bone marrow-resident plasma cells (PCs), which normally function to support long-
term humoral immunity. Normal PCs are uniquely programmed to generate significant 
amounts of antibody/immunoglobulin (Ig) while surviving indefinitely in the bone 
marrow microenvironment.2 As MM cells are the transformed version of PCs, they 
often produce large amounts of Ig, albeit completely non-functional. It is hence unsur-
prising that the complications from MM arise not only from invasive MM cell growth 
primarily in the bone and bone marrow but also from the production of aberrant Ig. 
Symptoms from the former include bone pain, osteolytic lesions, hypercalcemia, and 
cytopenias.3 The latter can result in a panoply of problems, including neuropathy and 
renal injury, which can occur through myriad mechanisms.4 In the extreme, MM cells 
can produce enough Ig to increase the viscosity of serum two- to fourfold, resulting 
in the rare but potentially fatal hyperviscosity syndrome.5
The exact nature of measurable malignant Ig can vary; MM Ig typically can be 
detected in serum and/or urine as 1) high concentrations of a full Ig molecule consist-
ing of heavy and light chains bound together; 2) high concentrations of the full Ig 
molecule plus high concentrations of light chains unbound to heavy chain (free light 
chains [FLCs]); or 3) primarily FLC in the presence of very small amounts or even 
no complete Ig whatsoever. A fourth entity exists, which is production of free heavy 
chain in the absence of bound light chain, but this is very rare.
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MM cells generally remain in the bone marrow with 
usually very low numbers of MM cells circulating in blood, 
but Ig circulates and its concentration in serum and urine 
generally correlates with total PC burden. Drawing blood 
and collecting urine are far simpler than repeat bone marrow 
biopsies, and so longitudinal monitoring of the concentration 
of monoclonal Ig as a surrogate for direct measurements of 
tumor burden has evolved as critical to the assessment of 
treatment responses and disease progression in MM. The tests 
most useful for following Ig are serum protein electrophoresis 
(SPEP) and urine protein electrophoresis (UPEP), serum and 
urine immunofixation electrophoresis (IFE), and the serum 
free light chain (SFLC) assay.6,7 Most patients’ MM can be 
accurately monitored using some combination of these tests. 
Consensus response criteria for determining effectiveness 
of MM therapy in clinical trials and off protocol are largely 
based on this panel.8
Interestingly, it has been observed since the 1950s that a 
very small subset of the myeloma population is functionally 
non-secreting, that is, there is no detectable monoclonal Ig 
by electrophoresis of the serum or urine.9–11 Initial reports 
estimated that these non-secretory multiple myelomas 
(NSMMs) represented anywhere from 3% to 5% of the total 
MM population.9 However, advances in the detection of 
SFLCs by high-sensitivity enzyme-linked immunosorbent 
assay (ELISA) have demonstrated that most of these NSMMs 
were probably oligosecretors – that is, their MM produced 
primarily or solely SFLC in the absence of heavy chain. FLCs 
are difficult to detect by standard SPEP and serum IFE.12 The 
routine use of the ELISA-based SFLC assay has revealed in 
most recent studies that the proportion of true NSMM, mean-
ing MM that secretes no measurable monoclonal heavy or 
light chain at all, is closer to ,1%–2% of all MMs.13
This review discusses the epidemiology of NSMM, the 
known physiologic underpinnings of non-secretion, and the 
clinical implications of non-secretion for diagnosis, treat-
ment, and prognosis.
Ig synthesis and secretion by normal 
long-lived PCs
To understand the mechanisms underpinning NSMM, it is 
critical to first understand the biology of Ig synthesis and 
secretion by PCs, which is detailed in a 2005 review by 
Shapiro-Shelef and Calame.14 In brief, it has been shown that 
a specific cascade of genetic signals mediated by BLIMP1 and 
IRF4 are necessary to begin derepression and enhancement, 
respectively, of the Ig genes. Fully formed Ig is composed 
of two heavy chains (IgH) and two light chains (IgL). The 
heavy chains define the Ig isotype (IgM, IgG, IgA, and IgE), 
and the light chains are one of two isotypes, either kappa 
or lambda. By the time a B cell is terminally differentiated 
into a PC, the appropriate gene rearrangements have already 
occurred such that the Ig produced will be restricted to one 
IgH isotype, one IgL isotype, and one idiotype (defined as 
the antigen-specific sequence of the variable region of Ig), 
resulting in an antigen-specific, symmetrical Ig molecule. 
BLIMP1 is also required to derepress the secretable (mu) 
form of the IgH mRNA, so that the full Ig molecule may 
be secreted into the extracellular environment. The PC also 
depends upon a physiologic unfolded protein response for 
appropriate endoplasmic reticulum expansion required to 
produce significant amounts of secretable Ig. This process 
is further enhanced by a number of chaperone and folding 
proteins, which help to post-translationally modify and shuttle 
the Ig molecule to the cell membrane for eventual secretion. 
Unsurprisingly, errors at any step in the pathway – be it 
heavy-chain synthesis, light-chain synthesis, Ig assembly, 
transport, or secretion – could lead to altered production and 
secretion pathways seen in both secretory MM and NSMM. 
Figure 1 visually depicts this process.
The initial reports hinting at the existence of a non-
secretory variant of MM came decades ago from patients 
who had MM by bone marrow biopsy and yet did not produce 
detectable Ig on either SPEP or UPEP.15 At the time, it was 
not clear whether the MM cells produced no Ig whatsoever 
or if Ig was synthesized but not secreted from the cell. In 
1970, Hurez et al16 demonstrated that some NSMM cells do 
indeed produce Ig that becomes trapped within the cytoplasm 
and is rapidly degraded. In a follow-up study by the same 
group,17 they observed that the surface or intracellular Ig of 
NSMM is restricted to either the light or heavy chain alone. 
This is in direct contrast to secretory myeloma, which is 
observed to secrete both heavy and light chains in 75% of 
cases.18 These data suggest that the “evolution” of NSMM 
cells may be stepwise from fully secretory MM to MM that 
loses production of heavy chain and then in a subsequent step 
loses production of light chain. Consistent with this hypoth-
esis is the fact that in this study and as it has been observed 
elsewhere as discussed earlier in this manuscript, most of the 
NSMMs initially identified were actually FLC secretors and 
the “non-secretory” finding was largely attributable to unde-
tected FLCs. The International Myeloma Working Group still 
defines NSMM as MM lacking monoclonal protein by serum 
or urine immunofixation, which can include light-chain MM 
with quite high levels of monoclonal FLCs detected solely 
by the SFLC assay.12,19 However, one can argue that this 
definition is perhaps a misnomer in these cases, since the 
MM indeed is actively secreting a component of Ig.
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One can more accurately subclassify cases of NSMM 
into at least four distinct categories with separate molecular 
mechanisms (Figure 2):
1. Oligosecretors/FLC-restricted MMs: Oligosecretors/
FLC-restricted MM has been discussed, and most cases 
can be followed by SFLC assay.
2. Non-producers: At least 12 patients have been described 
whose MM is non-secretory due to a complete, true 
absence of any Ig production whatsoever.20 Such rare 
patients would not be able to be monitored by either 
traditional methods or intracellular immunofluorescence, 
which can be used to detect monoclonal Ig in the cyto-
plasm of many cases of NSMM. It is hypothesized that 
the mechanism of non-production is the loss of SFLC 
secretion by MM clones, which were initially FLC secre-
tors, although this has not been definitively proven.
Figure 2 Defining the terms of NSMM.
Abbreviations: NSMM, non-secretory multiple myeloma; PC, plasma cell; MM, multiple myeloma; SFLC, serum free light chain; ig, immunoglobulin.
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Figure 1 Mechanism of synthesis and secretion of ig by PC and sources of error.
Notes: (1) Transcription-aberrant vDJ arrangements, splice site mutations, and stop codons can produce truncated (or no) heavy chain and less often light chain. (2) Folding, 
if appropriate, can lead to further processing. (3) if not, it leads to protein degradation, often via the proteasome (2a). (3) Multimeric proteins are assembled, and post-
translational modifications are made to assist in transport to the cell membrane. (4) Igs are transported to the surface in vesicles. (5) If folded and modified appropriately, Igs 
will be secreted from the cells (top). if there are errors, igs will be secreted in vesicles (bottom) and may not be detectable by SPeP, iFe, or SFLC analysis.
Abbreviations: Ig, immunoglobulin; PC, plasma cell; SPEP, serum protein electrophoresis; IFE, immunofixation electrophoresis; VDJ, variable-diversity-joining.
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3. True non-secretors: These MM cells produce Ig mol-
ecules but are unable to secrete them (the variety of 
mechanisms by which this occurs is discussed in detail 
in the following).10,21
4. False non-secretors: Initially Decourt et al21 and since 
then others have referred to certain cases as “false non-
secretors.” These are MM variants or related plasma cell 
diseases that had measurable intracellular Ig by immuno-
fluorescence but no measurable extracellular component 
by typical testing, despite clear pathological evidence that 
they were being secreted (such as Ig deposits found in renal 
biopsies, as can be found as part of the recently described 
entity monoclonal gammopathy of renal significance).21–23 
There are some data that suggest that these Igs are being 
secreted in vesicles via budding off of the cell membrane, 
rendering them undetectable in the serum. This, too, would 
represent a challenge for detection and treatment.
In this review, further use of the term NSMM refers to 
non-producers and true non-secretors, ie, subtypes of MM 
that truly have no serum or urine monoclonal Ig, partial 
(meaning light chain), or otherwise (Figure 2).
Mechanism of NSMM
The exact mechanisms that prevent either production 
or secretion of monoclonal Ig by NSMM remain poorly 
understood. As mentioned earlier, one competing hypoth-
esis argues that true NSMMs arise due to a sequential loss 
of secretion of first heavy chains and then light chains.17 
In individual case reports, it has been shown that true non-
secretors have lost the polyadenylation site that is necessary 
for extracellular Ig secretion.24 Other reports have shown 
that loss of the V domain of the heavy chain also prevents 
secretion and stimulates intracellular degradation.25 Interest-
ingly, in the same patient, the MM cells had also entirely 
lost light-chain production due to kappa-chain mutations.25 
A case report in 2004 also detailed a frameshift mutation in a 
patient with kappa-restricted MM. This mutation altered the 
location of cysteine residues that are critical for appropriate 
light-chain folding, resulting in an inability to interact with 
chaperone proteins and ultimately proteasome-mediated 
degradation.26
Interestingly, loss of ability to secrete the heavy chain (ie, 
light-chain restriction) appears to be a pro-survival characteris-
tic during clonal evolution in MM. The current leading hypoth-
esis is that production of heavy chain may be toxic to PCs.21 This 
toxicity may be related to the intracellular inclusions themselves 
(seen clinically in the so-called Mott cells), which can activate 
downstream apoptotic signaling pathways. Mechanistically, 
many cases of light-chain MM have been shown to have 
interruption of the IgH domain, typically via translocation, 
and the other locus may be defective due to non-functional 
VDJ (variable-diversity-joining) arrangements.27 One study in 
2002 found that 11 out of 14 NSMM patients had a t(11;14)
(q13;q32) rearrangement, which the authors postulated gave the 
cells a more “lymphoplasmacytic morphology” with a lower 
secreting capacity than MM cells without the translocation.20,28 
Interestingly, the same translocation was detected in the MM 
case report detailed earlier that also demonstrated the frameshift 
mutation in the gene coding the light-chain constant region, 
functionally preventing secretion of the kappa light chain.26 
Taken together, these examples bolster the hypothesis for a 
stepwise loss in secretion of the heavy and light chains as a 
possible mechanism for NSMM development.
Implications for prognosis
Given the rarity of NSMM in the overall MM popula-
tion, its clinical course and prognosis are not thoroughly 
characterized. Moreover, since monitoring of the Ig is an 
essential metric for tracking response to therapy and detect-
ing relapse, NSMM patients are almost universally excluded 
from clinical trials.29 The result is a substantive dearth of data 
for this population.
In 1986, Smith et al30 released a case series that included 
13 NSMM patients, in which NSMM patients had a median 
survival of 46 months compared to 22 months for secretors. 
At that time, ELISA-based SFLC testing was not com-
mercially available and therefore it is unclear how many 
of the NSMM patients actually had light-chain MMs. In a 
retrospective study by Chawla et al13 in 2015, the survival 
and prognosis of 124 NSMM patients were examined, and 
the study included SFLC testing where available. They 
demonstrated that time to progression, progression-free 
survival (PFS), and overall survival (OS) prior to 2001 were 
similar between NSMM patients and secretory MM patients. 
When they examined the years 2001–2012 – the time frame 
during which new therapeutics were broadly introduced – 
there was a marked increase in OS in both groups. However, 
it appeared that the improvement in OS was greater in the 
NSMM group. Interestingly, the survival gain was not seen in 
patients treated with high-dose chemotherapy and autologous 
stem cell transplantion.13,31
Diagnosis, treatment, and 
monitoring of NSMM in the clinic
The standardized workup put forth by the International 
Myeloma Working Group for any patient suspected of having 
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MM includes measurement of monoclonal Ig by SPEP, 
UPEP, serum and urine IFE, and SFLC analysis.32 All patients 
with suspected MM, including NSMM, should undergo 
bone marrow aspiration and biopsy with standard studies, 
including flow cytometry and CD138-enriched fluorescent 
in situ hybridization testing. Samples should also be stained 
for intracellular Ig if NSMM is suspected. As in all other 
forms of MM, NSMM requires myeloma-defining events 
and/or evidence of MM-mediated end organ damage such 
as hypercalcemia, anemia, or bone lesions to differentiate an 
asymptomatic MM precursor from true MM.7
Therapeutically, no data exist to suggest that NSMM 
responds differently to standard MM treatments. In fact, 
retrospective studies examining standard approaches13 and 
autologous stem cell transplantation (ASCT)13,33 are under-
powered for specifically examining NSMM, but as mentioned 
already, it appears that NSMM may do equally well if not 
better than secretory MM. Consequently, until data emerge to 
suggest other pathways, treatment of NSMM should follow 
the same guidelines as those provided for secretory MM.
Monitoring response, however, is where practice clearly 
deviates from secretory MM, in that clinicians’ inability 
to use serum and urine Ig studies as reliable surrogates for 
tumor burden presents a unique dilemma for clinical deci-
sion making in NSMM. Serial bone marrow studies facilitate 
direct examination of tumor burden and are the gold standard, 
but the cost, time, and patient discomfort associated with 
frequent bone marrow aspirations and biopsies make them 
suboptimal from the standpoint of practicality; hence, the 
focus turns to imaging.
Radiological findings by conventional X-rays frequently 
lag behind tumor response, and hence, X-rays are inadequate 
and more advanced imaging modalities are necessary. Spe-
cific data are lacking for imaging in NSMM, and as a result, 
they are extrapolated from secretory MM, where magnetic 
resonance imaging (MRI) and positron emission tomography 
(PET) are most well established.
The first relevant question is whether specific imaging 
techniques are abnormal in MM at baseline, prior to ini-
tiation of therapy, since response can only be monitored if 
abnormalities exist pre-intervention. Multiple case series 
examining the relative utility of MRI vs PET vs X-rays have 
been published but are difficult to interpret comparatively due 
to small numbers and heterogeneity. Walker et al34 showed 
that 74% of patients in the Arkansas Total Therapy series had 
focal lesions in bone marrow that were detectable by MRI. 
Similarly, in one other small study (n=46) in which PET/
CT, MRI, and X-rays were compared, MRI of spine–pelvis 
detected diagnostic abnormalities in 92% of patients, whereas 
72% had lesions on whole-body PET/CT.35 A relatively recent 
systematic review by Regelink et al36 observed that both MRI 
and PET had a sensitivity of .90% using X-rays as the gold 
standard (ie, MRI and PET individually detected abnor-
malities in .90% of patients who had abnormal findings on 
X-ray) and both modalities detected a higher total number of 
lesions than X-rays, suggesting that both techniques are more 
sensitive. These findings have been confirmed in one more 
recent study.37 Taken together, one concludes that PET/CT 
and MRI are more sensitive than X-rays for diagnosing MM, 
and MRI may be the most sensitive technique of all.
Equally important is determining whether abnormali-
ties uncovered by these modalities at baseline change with 
therapy, ie, whether they can be reliably used to follow 
response. One Italian study found that 76% of 192 patients 
going for ASCT for MM had detectable lesions by PET/CT 
at diagnosis and 35% still had detectable lesions after 
stem cell transplant. Lack of complete normalization of 
standardized uptake value activity post transplant strongly 
predicted both PFS and OS (hazard ratios [HRs] of 1.89 and 
3.9, respectively, P=0.03 for both).38 Similarly, the Arkansas 
group found that post induction, pre-transplant suppression 
of focal lesions detected on PET was predictive of improved 
OS (HR 0.33, P=0.001) and PFS (HR 0.47, P=0.13).34
Conversely, MRI has been the subject of fewer and 
smaller studies, and data are conflicting. For patients with 
diffuse marrow abnormalities by MRI at diagnosis, normal-
ization of the findings on whole-body MRI correlated well 
with response measured by conventional Ig markers in one 
study of 30 subjects. On the other hand, for patients present-
ing with focal marrow lesions on MRI (small myelomatous 
lesions that are measurable in size), only 33.5% of patients 
who achieved very good partial response or better response 
by standard response criteria8 had shrinkage of these lesions, 
suggesting inadequate sensitivity for detecting response.39 
This finding has been reproduced in one other similar study.40 
Hence, MRI may be inadequately sensitive for monitoring 
response in MM presenting with certain radiological findings 
in secretory MM, which in turn detracts from its appeal in 
NSMM. Add to that, the cost and time required for whole-
body MRI make it clinically impractical, and one realizes 
that MRI is likely to be suboptimal.
It is therefore concluded that whole-body PET/CT is 
imperfect but currently arguably the optimal non-invasive 
modality for following response in NSMM, when lesions 
are detectable at diagnosis. It is abnormal in the majority of 
patients, changes with overall response to chemotherapy, and 
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beyond that has been shown to be prognostic for both PFS 
and OS. MRI is likely more sensitive for detecting lesions at 
diagnosis, but the practical limitations and its relatively static 
nature despite tumor kill (ie, MRI does not reliably change 
with treatment response) make it inadequate for monitoring.
Finally, the gold standard for monitoring response in any 
form of MM, including NSMM, is directly measuring the 
tumor burden via bone marrow aspiration and biopsy. “Going 
to the source” is of course desirable from the perspective of 
avoiding surrogate response markers, including imaging. 
That said, the prospect of bone marrow biopsies every 
6–12 weeks indefinitely is unpalatable for patients. One other 
consideration is the fact that MM can be patchy; one thinks 
of MM as a diffuse process that uniformly invades the bone 
marrow throughout the body, but the fact that one can see 
focal marrow lesions on MRI and heterogeneous marrow 
18F-fluorodeoxyglucose-avidity on PET both suggest that 
the extent of marrow involvement at different sites can be 
heterogeneous within a single patient, and one can further 
infer that response determination via blindly obtained marrow 
samples may be subject to sampling error. That said, one small 
study suggested that bilaterally obtained marrow samples in 
MM showed similar results on both sides for both immuno-
histochemistry and flow cytometry,41 providing some reassur-
ance that standard unilateral posterior iliac crest bone marrow 
collections are indeed accurate for following NSMM.
Translating the data to actual clinical practice, for NSMM 
patients with detectable lesions on PET/CT at diagnosis, 
whole-body PET/CT was performed every 6–12 weeks 
with the interval decided based on the duration of treatment 
cycles and the clinical circumstances (more often for patients 
with aggressive disease and/or lack of other reliable clini-
cal indicators of response versus less often for patients with 
indolent disease and/or other clinical indicators that the MM is 
clearly responding, such as improvement in symptoms or cell 
counts). For patients in remission and undergoing long-term 
monitoring, perhaps on maintenance chemotherapy, PET/
CT every is undertaken 3–6 months. In these patients, bone 
marrow aspirations and biopsies were pursued approximately 
every 3–6 months during induction, depending on the level of 
confidence in other response assessments and then space those 
out as well once patients move into the remission/maintenance 
phase. Specifically, for a patient with PET/CT that clearly and 
believably reflects the MM disease burden and who is clinically 
doing well, bone marrow testing were pursued approximately 
yearly. For patients who need to be monitored more closely, 
bone marrow testing is done every 3–6 months.
In patients with NSMM that cannot be followed by 
PET/CT, one must follow their disease by serial bone marrow 
aspirations and biopsies approximately every 4–8 weeks 
during induction, again depending on clinical factors 
described earlier, more often, especially early in therapy, 
for patients requiring closer monitoring versus less often for 
patients who are felt to warrant a longer interval between 
assessments. Once stably in remission, we perform bone 
marrow testing roughly once every 3–6 months.
Discussion
NSMM is a rare variant of MM that is becoming even more 
uncommon as methods of Ig detection become more sensi-
tive. Because of its rarity and its systematic and purposeful 
exclusion from clinical trials, there is a paucity of data 
regarding prognosis. Based on the current studies available, 
however, NSMM appears to perhaps be less aggressive than 
secretory MM.
From a biological perspective, this seems counterintui-
tive. Ig production is metabolically disadvantageous to the 
cell (since a cell is required to expend energy in its produc-
tion). More efficient energy management should lead to 
a proliferative and survival advantage for NSMM, which 
conceivably should confer a poorer prognosis clinically. 
One would also perhaps expect that eventually all MM 
would become NSMM and thereby appropriate that meta-
bolic advantage, although that rarely occurs clinically. We 
hypothesize that that incongruence could be explained by: 
1) the fact that renal insufficiency is uncommon in NSMM,11,30 
and renal dysfunction is associated with worse mortality4,42,43; 
2) preclinical models that show that NSMM may express 
light chains on class I major histocompatibility complex 
receptors, thereby stimulating anti-NSMM cytotoxic T-cell 
responses44,45; 3) differential response to therapy. Because 
many NSMM cells are likely dependent on the proteasome 
for degradation of retained protein products, they may 
be more sensitive to proteasome-targeting agents such as 
bortezomib. Unfortunately, due to systematic exclusion of 
NSMM from clinical trials, there are no good data to defini-
tively suggest that NSMM patients respond more rapidly or 
durably to proteasome inhibitors. 
In thinking about why MM does not more frequently 
become NSMM, it may be that in NSMM subclones may 
develop frequently but may undergo preferential elimina-
tion by drugs, the immune system, or both, for reasons listed 
above.
A limitation in hypotheses 2 and 3 is that both are 
grounded in the inaccurate assumption that all NSMM cells 
retain misfolded Ig proteins. MM in a vanishingly small 
number of patients produces neither heavy nor light chain 
of any kind. These non-producers would appear to lack any 
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of the hypothesized disadvantages of Ig synthesis, such as 
increased susceptibility to immune-mediated cytotoxicity or 
proteasome inhibition, which should increase the prevalence 
of this phenomenon but does not. Ultimately, it may simply 
be the number of gene mutations necessary to render all 
heavy-chain and light-chain genes inactive that limits the 
conversion of secretory MM to NSMM, but clearly further 
studies in PC biology and MM pathogenesis are needed.
Overall, NSMM is rare and its biology is incompletely 
understood. Therapy based on contemporary data should 
match that for secretory MM. In contrast, monitoring NSMM 
relies far more heavily on PET/CT scans and frequent bone 
marrow sampling. Ultimately, clinical trials dedicated to 
NSMM would be very useful, although the challenges of 
NSMM’s rarity and the fact that an NSMM trial would 
require a complete revision of the well-established response 
criteria used to follow secretory forms of MM make such a 
prospective trial unlikely.
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